Posted on June 15th, 2015
Roberto Bellini has served as President and CEO of BELLUS Health since January 1, 2010.
Company OverviewBELLUS Health (TSX: BLU) (OTC: BLUSF) is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program is KIACTA™, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics. The Phase III Confirmatory Study completed its targeted enrollment in May 2014 and is expected to conclude in 2016. KIACTA™ is also being developed as a treatment in a second indication called sarcoidosis, a rare inflammatory condition that affects the lungs. In addition, BELLUS Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli ("sHUS"). sHUS often leads to dialysis, chronic kidney disease and in some ca... Learn More »
The World Orphan Drug Conference (WODC) took place on April 23rd-24th, 2015. This conference is an annual gauge of the r...Read More »
Posted on June 8th, 2015
I recently attended the Annual American Society for Clinical Oncology (ASCO) meetings in Chicago. It is a very busy conf...Read More »
Posted on June 1st, 2015
Interest in orphan diseases has increased at a feverish pace over the course of the last decade. But it was not always t...Read More »
Posted on May 27th, 2015
Last Thursday we held our “SF Explorers Meeting,” where we invite technical staff and advisers to meet with our boar...Read More »
Posted on May 20th, 2015
Today’s press release announcing my participation in H.C. Wainwright’s clinical development panel discussion at ASCO...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
The Chairman's Blog is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. The Chairman's Blog enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. Learn More »